Posted Feb. 8, 2013 at 8:55 a.m.
Research Triangle Park, N.C. — Drug development firm Tranzyme, its stock trading well under $1, has decided to explore a possible sale, merger or other options that can "maximize value to its stockholders."...
Tranzyme board decides to explore possible sale or merger
Post a comment
Print this blog postE-mail blog post
Share
Research Triangle Park, N.C. — Drug development firm Tranzyme, its stock trading well under $1, has decided to explore a possible sale, merger or other options that can "maximize value to its stockholders."...
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 WRAL Tech Wire. All rights reserved.Please log in to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows